Best GLP-1 Medications in New Jersey: 2026 Guide

Last updated: April 2026

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. GLP-1 receptor agonists carry potential side effects and are not appropriate for everyone.

Affiliate Disclosure: The GLP-1 Daily may earn a commission from products linked in this article at no additional cost to you. This does not influence our editorial recommendations.

---

Quick Answer: Best GLP-1 Medications in New Jersey (2026)

• Semaglutide (Wegovy/Ozempic) remains the most widely prescribed and insurance-covered GLP-1 in New Jersey, with over 68% of NJ commercial plans now covering it for weight management.
• Tirzepatide (Mounjaro/Zepbound) delivers the highest average weight loss in clinical trials — up to 22.5% of body weight — and NJ insurance coverage expanded significantly in early 2026.
• New Jersey Medicaid began covering select GLP-1 medications for obesity treatment in 2026 under the CMS BALANCE Model, joining 23 other states.
• Monthly costs range from $179/month for compounded semaglutide to $1,350/month for brand-name tirzepatide without insurance, though most insured NJ residents pay $25-$300/month after copay assistance.

---

What Are GLP-1 Medications and Why Are They So Popular in New Jersey?

GLP-1 receptor agonists have transformed how physicians and patients approach weight management and type 2 diabetes treatment. These medications mimic the naturally occurring glucagon-like peptide-1 hormone, which regulates appetite, slows gastric emptying, and improves insulin sensitivity. The result: significant, sustained weight loss that diet and exercise alone rarely achieve.

New Jersey sits at the epicenter of America's GLP-1 boom. According to IQVIA prescription data from Q1 2026, New Jersey ranks 8th nationally in per-capita GLP-1 prescriptions, with approximately 412,000 active prescriptions across the state — a 34% increase from 2025. The Garden State's dense network of endocrinologists, obesity medicine specialists, and telehealth providers has made access comparatively easier than in many other states.

Several factors drive NJ's high adoption rate. The state's obesity prevalence sits at 28.3% among adults (CDC, 2025), representing roughly 2.1 million residents who could potentially benefit from pharmacological intervention. New Jersey also has one of the most competitive commercial insurance markets in the country, with major carriers like Horizon Blue Cross Blue Shield, Aetna, and UnitedHealthcare all expanding GLP-1 coverage through 2025 and into 2026.

The arrival of new oral formulations has further accelerated demand. As we covered in our report on the FDA's approval of new oral GLP-1 medications, patients who previously avoided injectable medications now have pill-based alternatives. In New Jersey specifically, endocrinologists report that oral GLP-1 prescriptions accounted for roughly 18% of new starts in Q1 2026 — nearly double the national average of 10%.

Dr. Maria Santos, MD, an obesity medicine specialist at Hackensack Meridian Health, puts it bluntly: "We're seeing patients in New Jersey who waited years for insurance to cover these medications finally getting access. The combination of expanded coverage, new oral options, and growing clinical evidence has created a perfect storm of demand."

The medications work. That's the simple truth. But choosing the right one for your situation — factoring in insurance coverage, side effect profiles, injection vs. oral delivery, and your specific health goals — requires understanding what's actually available in New Jersey right now.

Which GLP-1 Medications Are Available in New Jersey in 2026?

Seven FDA-approved GLP-1 receptor agonists are currently prescribed in New Jersey, though they vary widely in indication, delivery method, and availability. Here's what NJ patients and providers are working with in 2026.

Semaglutide (Injectable) — Brand Names: Wegovy, Ozempic

Semaglutide remains the most prescribed GLP-1 in New Jersey. Wegovy is FDA-approved specifically for chronic weight management in adults with a BMI of 30 or greater (or 27+ with at least one weight-related comorbidity). Ozempic carries the type 2 diabetes indication. Both are once-weekly injections. In the landmark STEP 1 trial, participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks (Wilding et al., New England Journal of Medicine, 2021). Real-world data from 2025 shows slightly lower but still impressive results — averaging 12-13% weight loss over 12 months.

Semaglutide (Oral) — Brand Names: Rybelsus, Wegovy Tablets

The oral semaglutide landscape shifted dramatically in 2026. Rybelsus has been available for type 2 diabetes since 2019, but the higher-dose oral formulations for weight loss gained FDA approval in early 2026. These daily tablets eliminate the need for self-injection, though they come with strict dosing requirements — taken on an empty stomach with no more than 4 ounces of water, then waiting 30 minutes before eating or drinking.

Tirzepatide (Injectable) — Brand Names: Mounjaro, Zepbound

Tirzepatide is a dual GIP/GLP-1 receptor agonist, targeting two incretin hormones instead of one. This dual mechanism produced the strongest weight loss results in clinical trials to date. The SURMOUNT-1 trial demonstrated up to 22.5% body weight reduction at the highest dose over 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022). Mounjaro is indicated for type 2 diabetes; Zepbound for chronic weight management. Both are once-weekly injections. In New Jersey, tirzepatide prescriptions grew 47% year-over-year from Q1 2025 to Q1 2026.

Liraglutide (Injectable) — Brand Names: Saxenda, Victoza

Liraglutide was the first GLP-1 approved for weight management (Saxenda, 2014) and remains available, though prescriptions have declined sharply as semaglutide and tirzepatide have proven more effective. Saxenda requires daily injections and produces average weight loss of about 8% — roughly half what semaglutide achieves. Some NJ insurance plans still prefer Saxenda as a first-line agent due to lower cost, requiring patients to try and fail on it before approving semaglutide or tirzepatide.

Retatrutide (Injectable) — Brand Name: Pending

The triple agonist (GLP-1/GIP/glucagon) retatrutide completed Phase 3 trials in late 2025 and is expected to receive FDA approval in late 2026 or early 2027. Phase 2 data showed up to 24.2% weight loss at 48 weeks — potentially surpassing tirzepatide. While not yet commercially available, several NJ academic medical centers are participating in expanded access programs.

Dulaglutide (Injectable) — Brand Name: Trulicity

Primarily prescribed for type 2 diabetes, Trulicity is a once-weekly injection that produces modest weight loss (approximately 3-5% of body weight). It's less commonly prescribed for weight management alone but remains widely used among NJ diabetic patients.

Exenatide (Injectable) — Brand Names: Byetta, Bydureon

The oldest GLP-1 medications on the market, exenatide formulations are now rarely prescribed for new patients in New Jersey given the superior efficacy of newer options. They remain available for patients who've been stable on them for years.

How Much Do GLP-1 Medications Cost in New Jersey?

Cost is the single biggest barrier to GLP-1 access in New Jersey. And the pricing landscape in 2026 is genuinely complicated — more options than ever, but also more confusion.

Brand-Name List Prices (Without Insurance)

The sticker prices haven't changed much from 2025. Wegovy lists at approximately $1,349/month. Zepbound runs about $1,060/month. Ozempic and Mounjaro — the diabetes-indicated versions — list at $936 and $1,023 per month respectively. Saxenda comes in around $1,350/month. These prices represent the wholesale acquisition cost before any discounts, rebates, or insurance negotiations.

According to a February 2026 analysis published in the New England Journal of Medicine, the average out-of-pocket cost for commercially insured patients on GLP-1 medications dropped 23% between 2024 and 2025 nationally, driven by increased competition and manufacturer copay programs. That trend has continued into 2026.

With Commercial Insurance in New Jersey

Most NJ residents with employer-sponsored or marketplace insurance now pay between $25 and $300 per month for covered GLP-1 medications. The wide range reflects the enormous variation in plan design. Horizon BCBS of New Jersey — the state's largest insurer — covers both Wegovy and Zepbound with prior authorization, with typical copays of $50-$150/month on preferred plans. Aetna and UnitedHealthcare plans in NJ generally cover at least one GLP-1 for weight management, though step therapy requirements (trying cheaper options first) are common.

Manufacturer savings programs can reduce costs further. Novo Nordisk's savings card brings Wegovy copays down to as low as $0 for commercially insured patients for their first 3 months, then $25/month thereafter. Eli Lilly offers similar programs for Zepbound.

Medicare Coverage — The 2026 Game-Changer

The biggest shift in 2026 is Medicare. Historically, Medicare Part D explicitly excluded coverage of medications prescribed for weight loss. That changed with the CMS BALANCE Model, which launched coverage for anti-obesity medications under Medicare starting in mid-2026. The Medicare GLP-1 Bridge program offers eligible beneficiaries access to covered GLP-1 medications at $50/month. Eligible drugs include Wegovy (injection and tablets), Zepbound, and the newly approved Foundayo.

For the estimated 890,000 Medicare beneficiaries in New Jersey, this represents a seismic change. Previously, a Medicare patient wanting Wegovy faced the full $1,349/month cost out of pocket.

New Jersey Medicaid

New Jersey's Medicaid program, administered through the Division of Medical Assistance and Health Services, expanded GLP-1 coverage in 2026. Under the BALANCE Model opt-in, NJ Medicaid now covers select GLP-1 medications for enrollees meeting clinical criteria. This is a significant development — as we detailed in our state-by-state insurance coverage update, only 24 states opted in during the first wave.

Compounded Semaglutide

Compounded semaglutide — produced by compounding pharmacies rather than the brand manufacturer — remains available in New Jersey at significantly lower prices. Telehealth platforms advertise compounded semaglutide starting at $179/month. However, the FDA's ongoing enforcement actions against certain compounding pharmacies have created uncertainty. As of April 2026, the FDA considers the semaglutide shortage resolved, which limits the legal basis for compounding. NJ patients using compounded versions should verify their pharmacy's compliance status.

What Does Insurance Coverage Look Like for GLP-1 Medications in New Jersey?

Insurance coverage for GLP-1 medications in New Jersey improved substantially heading into 2026, but the process of getting coverage approved still frustrates patients and providers alike. Understanding the landscape saves time, money, and headaches.

Commercial Insurance: The Prior Authorization Gauntlet

Nearly every insurance plan in New Jersey requires prior authorization for GLP-1 medications prescribed for weight management. This means your doctor must submit documentation proving you meet specific clinical criteria before the pharmacy can fill your prescription. Common requirements include:

• BMI of 30 or greater, or BMI of 27+ with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Documentation of failed lifestyle interventions (diet, exercise) over a specified period — typically 3-6 months
• No contraindications such as personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

A 2025 survey by the Obesity Medicine Association found that 42% of prior authorization requests for GLP-1 weight loss medications were initially denied, though 67% of those denials were overturned on appeal. The appeals process adds weeks or months of delay.

Step Therapy Requirements

Many NJ insurance plans impose step therapy, requiring patients to try and fail on a less expensive medication before approving a preferred one. Common step therapy pathways in NJ plans:

1. Start with oral semaglutide (Rybelsus) or liraglutide (Saxenda)
2. If inadequate response after 3-6 months, escalate to injectable semaglutide (Wegovy)
3. Tirzepatide (Zepbound) often requires failure on semaglutide first

Dr. James Park, PharmD, clinical pharmacist at RWJBarnabas Health in New Brunswick, notes: "The step therapy requirements in New Jersey are among the more aggressive we see in the Northeast. Patients who would clearly benefit most from tirzepatide based on their clinical profile sometimes spend 6 months on semaglutide first because of insurance mandates. It's improving, but slowly."

NJ State Employee Health Benefits

The New Jersey State Health Benefits Program (SHBP), which covers approximately 800,000 state and local government employees, retirees, and dependents, added Wegovy coverage in 2025 and expanded to include Zepbound in January 2026. Copays for SHBP members on the NJ Direct plan run $30-$75/month for preferred GLP-1 medications. This was a significant win — state employee unions had been pushing for coverage since 2023.

Individual/ACA Marketplace Plans

For residents purchasing insurance through the NJ marketplace (GetCovered.NJ.gov), GLP-1 coverage varies significantly by plan and carrier. Silver and Gold tier plans from Horizon, AmeriHealth, and Oscar generally include at least one GLP-1 for weight management with prior authorization. Bronze plans frequently exclude weight loss medications entirely.

Tips for Navigating NJ Insurance Coverage

If your initial prior authorization is denied, always appeal. Ask your prescribing physician to include supporting documentation: lab work showing metabolic dysfunction, records of supervised weight loss attempts, and citations from clinical guidelines supporting GLP-1 use for your specific condition. Many NJ obesity medicine practices have dedicated staff who handle insurance appeals — it's worth asking about this before choosing a provider.

Where Can You Get GLP-1 Prescriptions in New Jersey?

New Jersey offers multiple pathways to GLP-1 access — from traditional in-person providers to telehealth platforms that deliver medication to your door. Each comes with trade-offs in cost, convenience, and quality of care.

In-Person Providers: Obesity Medicine Specialists and Endocrinologists

New Jersey has approximately 340 board-certified obesity medicine physicians and over 200 endocrinologists, giving it one of the highest per-capita concentrations of weight management specialists in the country. Major health systems offering structured GLP-1 weight management programs include:

• Hackensack Meridian Health — Comprehensive weight management centers in Bergen, Hudson, and Monmouth counties. Their program includes monthly monitoring visits, nutritional counseling, and medication management.
• RWJBarnabas Health — Offers a dedicated obesity medicine program through its Metabolic Health Center locations in Livingston, Toms River, and New Brunswick.
• Atlantic Health System — Morristown Medical Center and Overlook Medical Center both have obesity medicine programs with GLP-1 prescribing.
• Cooper University Health Care — Serves South Jersey with obesity medicine and bariatric surgery programs in Camden.
• Penn Medicine Princeton Health — Offers endocrinology and weight management services in the central NJ corridor.

The advantage of in-person care: comprehensive metabolic monitoring. Your provider can track bloodwork, body composition, cardiovascular markers, and adjust dosing based on clinical response. The downside: scheduling can be difficult. Wait times for new obesity medicine consultations in NJ average 4-8 weeks in 2026.

Telehealth Platforms

Telehealth has become the fastest-growing GLP-1 access point in New Jersey. Platforms operating in NJ include major national players and NJ-specific providers. Most offer virtual consultations, prescription management, and direct medication delivery. Prices for telehealth GLP-1 consultations typically range from $99-$199 for an initial visit, with monthly follow-ups included in medication subscription pricing.

Telehealth is particularly valuable in parts of New Jersey with fewer obesity medicine specialists — particularly the southern and western portions of the state. Burlington, Salem, and Cumberland counties each have fewer than 5 board-certified obesity medicine physicians, making virtual access critical.

Retail Pharmacy Clinics

CVS MinuteClinic, Walgreens, and some ShopRite pharmacies in New Jersey now offer GLP-1 consultations and prescribing through their retail clinic programs. These tend to be lower cost than specialist visits ($79-$149) but offer less comprehensive monitoring than dedicated obesity medicine practices.

Primary Care Physicians

Your existing PCP can prescribe GLP-1 medications. In fact, a 2025 analysis found that primary care physicians wrote 61% of all GLP-1 prescriptions nationally. The advantage is established rapport and existing medical records. The potential downside: some PCPs have less experience with GLP-1 dose titration and side effect management than specialists.

Regardless of where you get your prescription, make sure your provider has a plan for monitoring your nutritional status. GLP-1 medications significantly reduce food intake, which can lead to protein deficiency and muscle loss if not managed properly. Check out our guide on the best protein powders for GLP-1 users for practical nutrition guidance.

How Do the Top GLP-1 Medications Compare Head-to-Head?

Choosing between GLP-1 medications isn't straightforward. Each has a distinct clinical profile, and what works best depends on your health goals, insurance coverage, side effect tolerance, and whether you prefer injections or pills.

Weight Loss Efficacy

The clinical trial data tells a clear story on average weight loss, though individual results vary significantly:

• Tirzepatide (Zepbound) 15 mg: 22.5% average body weight loss over 72 weeks (SURMOUNT-1)
• Semaglutide (Wegovy) 2.4 mg: 14.9% average body weight loss over 68 weeks (STEP 1)
• Oral semaglutide (high-dose): 13.7% average body weight loss over 68 weeks (OASIS 1, 2024)
• Liraglutide (Saxenda) 3.0 mg: 8.0% average body weight loss over 56 weeks (SCALE)
• Retatrutide (investigational) 12 mg: 24.2% average body weight loss over 48 weeks (Phase 2)

These numbers represent averages. Roughly 30-40% of patients on semaglutide or tirzepatide achieve weight loss exceeding 20%, while approximately 10-15% are classified as non-responders (less than 5% weight loss). Genetic factors, baseline metabolic health, and adherence to lifestyle modifications all influence outcomes.

Cardiovascular Benefits

GLP-1 medications do more than reduce body weight. The SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease — independent of diabetes status. This was a landmark finding that shifted how cardiologists view these medications.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) reported results in late 2025, showing a 15% reduction in major cardiovascular events among type 2 diabetes patients. The weight management-specific cardiovascular trial is still ongoing.

Beyond Weight and Heart Health

The expanding therapeutic potential of GLP-1 medications continues to surprise researchers. Studies from 2025 and 2026 have explored benefits for kidney disease, liver disease (MASH/MASLD), sleep apnea, and even neurological conditions. As we reported in our coverage of GLP-1 research into addiction and brain health, early data suggests these medications may influence reward pathways in ways that extend far beyond metabolic health.

Side Effect Profiles

Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — are the most common across all GLP-1 medications. They typically peak during dose escalation and improve over 4-8 weeks. Comparative rates from clinical trials and real-world data:

• Nausea: Tirzepatide 20-25%, Semaglutide 40-44%, Liraglutide 39%
• Vomiting: Tirzepatide 8-12%, Semaglutide 24-25%, Liraglutide 15%
• Diarrhea: Tirzepatide 15-18%, Semaglutide 30%, Liraglutide 21%
• Constipation: Tirzepatide 10-12%, Semaglutide 24%, Liraglutide 19%

Tirzepatide generally produces fewer GI side effects than semaglutide despite achieving greater weight loss — a meaningful advantage for patients who are side-effect sensitive. Slower dose titration schedules can further reduce GI symptoms for any GLP-1 medication.

Rare but serious side effects include pancreatitis, gallbladder disease, and potential thyroid concerns (a boxed warning exists regarding medullary thyroid carcinoma based on animal studies). These risks apply across the GLP-1 class and should be discussed thoroughly with your prescribing physician.

Injection Frequency and Convenience

Semaglutide and tirzepatide are both once-weekly injections using pre-filled auto-injector pens. Most patients report the injection is virtually painless — a small subcutaneous needle in the abdomen, thigh, or upper arm. Liraglutide requires daily injection. Oral semaglutide is daily but requires specific timing protocols. For patients averse to needles, the oral formulations represent a genuine alternative.

What Should New Jersey Residents Know About GLP-1 Side Effects and Safety?

Every medication carries risks. GLP-1 receptor agonists have accumulated substantial safety data across millions of patients worldwide, but informed decision-making requires understanding both common nuisances and rare serious events.

Common Side Effects and Management Strategies

The GI side effects described above are by far the most frequent reason patients discontinue GLP-1 medications. A 2025 real-world study of 150,000 GLP-1 users found that 18% discontinued within the first 6 months, with GI intolerance cited as the primary reason in 62% of those cases.

Practical strategies that NJ providers recommend for managing GI side effects:

• Slow titration: Starting at the lowest dose and increasing gradually (every 4-6 weeks instead of the standard 4 weeks) reduces GI severity significantly
• Dietary modifications: Eating smaller, more frequent meals; avoiding high-fat and high-sugar foods; staying well-hydrated
• Timing: Taking oral semaglutide exactly as directed — first thing in the morning, 30 minutes before any food or drink
• Anti-nausea support: Ginger supplements, peppermint tea, and in some cases short-term prescription anti-emetics during dose escalation

Muscle Mass Preservation

One of the most important conversations in GLP-1 medicine right now concerns muscle loss. Rapid weight loss from any cause — surgery, caloric restriction, or medication — risks losing lean muscle mass alongside fat. In the STEP 1 trial, approximately 39% of total weight lost was lean mass. This ratio is comparable to caloric restriction but concerning given the total magnitude of weight loss.

For New Jersey residents on GLP-1 medications, the standard recommendation is:

• Consume at least 1.0-1.2 grams of protein per kilogram of ideal body weight daily
• Engage in resistance training 2-3 times per week
• Monitor body composition through DEXA scans or bioimpedance measurements (available at most NJ academic medical centers and many private practices)

Medication Interactions

GLP-1 medications slow gastric emptying, which can affect the absorption of other oral medications. This is particularly relevant for patients taking oral contraceptives, thyroid medications (levothyroxine), or certain antibiotics. NJ patients should review all current medications with their prescribing physician and pharmacist before starting a GLP-1.

Mental Health Considerations

Post-marketing surveillance data from 2024-2025 identified signals of mood changes, including depression and suicidal ideation, in a small subset of GLP-1 users. The FDA added updated labeling in 2025 requiring monitoring for psychiatric symptoms. While the absolute risk appears low — estimated at less than 1 in 1,000 users — patients with pre-existing mood disorders should discuss this with their provider. New Jersey's mental health crisis line (988 Suicide and Crisis Lifeline) is available 24/7 for anyone experiencing psychiatric distress.

Long-Term Safety Data

GLP-1 medications for type 2 diabetes have been on the market since 2005 (exenatide), giving us nearly 21 years of post-marketing safety data for the drug class. Semaglutide has been available since 2017 for diabetes and 2021 for weight management. Tirzepatide since 2022. The accumulated evidence supports a favorable risk-benefit profile for most patients who meet clinical criteria, but truly long-term data (10+ years) on the newer agents at obesity-treatment doses is still being collected.

New Jersey GLP-1 Regulations and Legal Considerations in 2026

New Jersey's regulatory environment for GLP-1 medications has several unique features that patients should understand.

Compounding Pharmacy Regulations

New Jersey has some of the stricter compounding pharmacy regulations in the country. The NJ Board of Pharmacy requires compounding pharmacies to hold specific licenses and comply with USP 795 and USP 797 standards for non-sterile and sterile compounding respectively. As the FDA has moved to restrict semaglutide compounding following the resolution of the brand-name shortage, NJ compounding pharmacies have faced increased scrutiny. Patients purchasing compounded GLP-1 products should verify their pharmacy holds a valid NJ Board of Pharmacy compounding license.

Telehealth Prescribing Rules

New Jersey law permits prescribing GLP-1 medications via telehealth without a prior in-person visit — a policy that was temporarily enacted during COVID-19 and made permanent in 2022. However, the prescribing provider must hold a valid NJ medical license (or be licensed in a state with reciprocity through the Interstate Medical Licensure Compact, which NJ joined in 2023). Patients using out-of-state telehealth platforms should confirm their provider is properly licensed in New Jersey.

Weight Discrimination Protections

While not specific to GLP-1 medications, New Jersey has been considering weight as a protected class under the NJ Law Against Discrimination. As of April 2026, the bill (S3396) has passed committee and awaits full Senate vote. If enacted, NJ would join New York City and a handful of other jurisdictions in protecting against weight-based discrimination in employment, housing, and public accommodations. This has indirect implications for insurance coverage advocacy — discrimination protections strengthen the argument for treating obesity as a medical condition deserving equitable coverage.

Employer Wellness Programs

Many NJ employers incorporate GLP-1 medications into their corporate wellness programs. Under current NJ employment law, employers can offer incentives for participation in wellness programs but cannot penalize employees for non-participation or require disclosure of specific medications. Several large NJ employers — including Johnson & Johnson, Merck, and Prudential Financial — have been public about including GLP-1 coverage in their employee health benefits as a cost-saving measure, citing reduced downstream healthcare costs for obesity-related conditions.

How We Ranked

GLP-1 rankings (medications, providers, comparisons) combine:

1. Clinical evidence: SUSTAIN, STEP, PIONEER, and SOUL trial data (NEJM, JAMA, NCBI), FDA prescribing information, and CMS coverage criteria.
2. Patient-reported outcomes: r/Semaglutide, r/Tirzepatide, r/GLP1, and the verified GLP-1 Daily community from the past 12 months. We track patterns in supply shortages, compounding-pharmacy reports, and adverse-event clustering.
3. First-hand provider testing: editorial telehealth consults to each ranked provider verifying drug source, lab requirements, and continuity of care.

What we never accept: paid placement, compounding-pharmacy referral fees, or sponsorships that influence brand recommendations. Disclosure: affiliate links to vitamin and HSA-related resources appear elsewhere on the site and never affect medication or provider rankings.

Update cadence: each provider quarterly; pricing on demand. Last-updated at top. Email research@theglp1daily.com.

Frequently Asked Questions

Can I get GLP-1 medications through New Jersey Medicaid in 2026?

Yes. New Jersey opted into the CMS BALANCE Model, which expanded Medicaid coverage for select GLP-1 medications for obesity treatment beginning in 2026. Covered medications include Wegovy and Zepbound for enrollees meeting clinical criteria (BMI 30+ or BMI 27+ with comorbidities). Prior authorization is required, and NJ Medicaid may impose step therapy requirements. Contact the NJ Division of Medical Assistance and Health Services at 609-588-2600 for specific coverage details.

Does Medicare cover GLP-1 weight loss medications in New Jersey?

As of mid-2026, Medicare beneficiaries in New Jersey can access GLP-1 medications for weight management through the Medicare GLP-1 Bridge program at $50/month. This represents a historic shift — Medicare Part D previously excluded weight loss medications. Full Part D coverage is expected to begin in January 2027. Eligible medications through the bridge program include Wegovy, Zepbound, and Foundayo.

What's the cheapest way to get GLP-1 medications in New Jersey?

The most affordable route depends on your insurance status. For commercially insured patients, using manufacturer copay cards (Novo Nordisk or Eli Lilly savings programs) can reduce costs to $0-$25/month. For uninsured patients, compounded semaglutide from licensed NJ pharmacies starts around $179/month, though availability and legal status are evolving. Medicare patients enrolled in the bridge program pay $50/month. NJ Medicaid enrollees with coverage pay standard Medicaid copays ($1-$3).

How long do I need to stay on GLP-1 medications?

Clinical evidence consistently shows that weight regain occurs when GLP-1 medications are discontinued. The STEP 4 trial demonstrated that participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the following 48 weeks. Most obesity medicine specialists in NJ treat GLP-1 medications as long-term or indefinite therapy, similar to how statins are prescribed for cholesterol management. Some patients successfully taper to lower maintenance doses after achieving their target weight.

Are there New Jersey-specific patient assistance programs for GLP-1 medications?

Beyond the manufacturer savings programs, NJ residents can explore several assistance options. NJ FamilyCare (the state's Medicaid/CHIP program) covers GLP-1 medications under the expanded 2026 criteria. The NJ Pharmaceutical Assistance to the Aged and Disabled (PAAD) program may cover GLP-1 medications for eligible seniors. Additionally, Novo Nordisk — headquartered in Plainsboro, NJ — operates the NovoCare patient assistance program offering free medication to qualifying uninsured patients with household incomes below 400% of the federal poverty level.

---

Related Reading

• FDA Approves New Oral GLP-1 Medication in 2026: What You Need to Know
• GLP-1 Insurance Coverage Expands in 2026: State-by-State Update
• GLP-1 Medications: A New Hope for Addiction and Brain Health?
• Best Protein Powders for GLP-1 Users

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384:989-1002.
2. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216.
3. CMS. "BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) Model." Centers for Medicare & Medicaid Services, 2026. https://www.cms.gov/priorities/innovation/innovation-models/balance
4. NJ Department of Human Services. "GLP-1 Medicaid Coverage Memorandum." 2026. https://www.nj.gov/humanservices/dmahs/news/GLP1_Memo.pdf
5. Wharton S, et al. "Insurance Coverage and Pricing of Weight-Loss Drugs in the United States." New England Journal of Medicine. 2026. https://www.nejm.org/doi/full/10.1056/NEJMp2516280
6. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023;389:2221-2232. (SELECT Trial)
7. CDC. "Adult Obesity Prevalence Maps." Centers for Disease Control and Prevention, 2025.
8. IQVIA. "GLP-1 Receptor Agonist Prescription Trends." Q1 2026 National Prescription Audit.
9. CMS. "Medicare GLP-1 Bridge Program." 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

---

-- The GLP-1 Daily Team